Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.
Hye-Young KimSeong-Beom ParkEun-Sil KangSang-Min LeeHyun-Jin KimMatthew WassermanPublished in: Human vaccines & immunotherapeutics (2020)
A NIP using PCV13 was estimated to have a more substantial public health impact and be cost-saving compared to a program with PCV10 due to broader serotype coverage.